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Summary
Miller-Dieker syndrome (MDS), a disorder manifesting the severe brain malformation lissencephaly
("smooth brain"), is caused, in the majority of cases, by a chromosomal microdeletion of the distal short
arm of chromosome 17. Using human chromosome 17-specific DNA probes, we have begun a molecular
dissection of the critical region for MDS. To localize cloned DNA sequences to the MDS critical region, a
human-rodent somatic cell hybrid panel was constructed which includes hybrids containing the abnormal
chromosome 17 from three MDS patients with deletions of various sizes. Three genes (myosin heavy chain
2, tumor antigen p53, and RNA polymerase II) previously mapped to 17p were excluded from the MDS
deletion region and therefore are unlikely to play a role in its pathogenesis. In contrast, three highly poly-
morphic anonymous probes, YNZ22.1 (D17S5), YNH37.3 (D17S28), and 144-D6 (D17S34), were deleted
in each of four patients with visible deletions, including one with a ring chromosome 17 that is deleted for
a portion of the single telomeric prometaphase subband p13.3. In two MDS patients with normal chromo-
somes, a combination of somatic cell hybrid, RFLP, and densitometric studies demonstrated deletion for
YNZ22.1 and YNH37.3 in the paternally derived 17's of both patients, one of whom is also deleted for
144-D6. The results indicate that MDS can be caused by submicroscopic deletion and raises the possibility
that all MDS patients will prove to have deletions at a molecular level. The two probes lie within a critical
region of less than 3,000 kb and constitute potential starting points in the isolation of genes implicated in
the severe brain maldevelopment in MDS.
Introduction
Miller-Dieker syndrome (MDS) is a multiple-malforma-
tion syndrome characterized by type I lissencephaly and
characteristic facial appearance. Lissencephaly is a se-
vere brain malformation whereby the typical convolu-
tions (gyri and sulci) are absent and the brain surface
is smooth, conferring a figure-eight shape to the brain
(Miller 1963; Dieker et al. 1969; Jones et al. 1980);
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type I refers to the classical form with a four-layered
cortex. The specific sequelae of lissencephaly include
bitemporal hollowing, a small jaw, and neurologic ab-
normalities. MDS can be differentiated from isolated
lissencephaly syndrome (ILS) by its characteristic fa-
cies (Dobyns et al. 1984).
Because of occasional familial recurrence, the etiol-
ogy ofMDS was once thought to follow an autosomal
recessive mode of inheritance. However, our studies have
shown chromosomal microdeletions in band 17pl3.3
in all three previously reported families with multiple
affected children and in four of six patients/sibships
in our series (Dobyns et al. 1983, 1984; Stratton et al.
1984; Greenberg et al. 1986). The smallest reported
deletion, found in a patient with a ring chromosome
17 in which the deletion is clearly limited to subband
17p13.3, precisely defines the critical region for MDS
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(Dobyns et al. 1983). Our subsequent experience indi-
cates that de novo deletions are more common than
unbalanced segregation of familial translocations in pa-
tients with cytogenetic deletions. As a result of these
developments, more reliable estimates of recurrence can
be made for genetic counseling, and prenatal diagnosis
by cytogenetic analysis is now possible and has been
accomplished (Stratton et al. 1984). However, several
patients with the complete MDS clinical phenotype
show no visible deletion on high-resolution analysis,
raising the possibility of submicroscopic deletion or het-
erogeneous etiology (including autosomal recessive in-
heritance).
MDS is thus one of the newest additions to a cate-
gory of genetic disorders termed "contiguous gene syn-
dromes" (Schmickel 1986) that are characterized by sub-
tle cytogenetic deletions detectable by high-resolution
chromosome analysis. The recognizable phenotypes of
these syndromes most likely result from deletion of sev-
eral functionally unrelated genes physically contiguous
on a chromosome. For Langer-Giedion (del 8q24),
Aniridia-Wilms tumor (del l1p13), Prader-Willi (del
15q11-12), and diGeorge (del 22q11) syndromes, as well
as for MDS, the deletion of multiple unrelated loci has
been proposed as a general causative mechanism
(Schmickel 1986; Francke 1987). Clinical variation
within these syndromes may be attributable to differ-
ent deletions involving overlapping sets of genes
(Schmickel 1986; Francke 1987). This provides a plau-
sible model for a genetic basis of isolated lissencephaly:
lissencephaly and the other physical abnormalities of
MDS may result from separate but contiguous loci on
17p, whereby mutation or deletion of only the putative
lissencephaly locus would be a possible etiology for
some cases of ILS.
There are several aspects of MDS amenable to mo-
lecular genetic analysis, and we address them in the
present study. We investigate the possibility that, as an
augment to high-resolution cytogenetic analysis, DNA
probes in this region may offer an easier and more reli-
able approach to laboratory diagnosis. Some or all MDS
patients with normal chromosomes may possess sub-
microscopic deletions detectable only by molecular tech-
niques, thus increasing the sensitivity of laboratory di-
agnosis. Second, molecular genetic analysis of 17p in
ILS patients is conducted in order to test the hypothesis
that a common link exists between the pathophysiol-
ogy of MDS and ILS. Ultimately, identification of ex-
pressed sequences within the MDS critical region may
lead to understanding of the developmental defects in
MDS, in particular those that cause the severe brain
malformation.
To initiate a molecular characterization of this re-
gion, we have used a detailed panel of somatic cell
hybrids to precisely map cloned sequences to 17p and
to identify those that are specific to the MDS critical
deletion region. We have regionally mapped cloned se-
quences from two categories: (1) genes already local-
ized to 17p and (2) a series of polymorphic anonymous
clones recently isolated by hybridization to minisatel-
lite core sequences (Nakamura et al. 1987). As an ex-
tension of earlier findings (vanTuinen et al. 1987a; van-
Tuinen and Ledbetter 1987), we now report three
independently isolated, highly polymorphic clones that
more narrowly define the MDS critical region.
Material and Methods
Clinical and Cytogenetic Evaluation
MDS and ILS criteria have been modified from our
previous criteria (Dobyns et al. 1984) on the basis of
subsequent experience. The minimal diagnostic criteria
for MDS that are used in the present study include (1)
type I lissencephaly (widespread with only a few abor-
tive gyri), (2) grossly normal or mildly dysplastic cere-
bellum, and (3) characteristic facial appearance. The
most consistent facial changes include bitemporal hol-
lowing; upturned nares; long, usually protuberant up-
per lip with thin vermillion border; relatively flattened
midface; and small jaw. Other facial changes, postna-
tal growth deficiency, and microcephaly are often but
not always observed. When present, midline calcifica-
tion adjacent to the third ventricle is probably pathog-
nomonic.
Diagnostic criteria for ILS are less strict and include
(1) type I lissencephaly similar to or less severe than
that in MDS, (2) grossly normal or mildly dysplastic
cerebellum, a criterion that excludes patients with
"cerebro-cerebellar" lissencephaly (Dobyns et al. 1985),
and (3) relatively normal facial appearance except for
bitemporal hollowing, small jaw, and sometimes
microcephaly. A few patients have had other minor fa-
cial changes, ones not typical of MDS. None have had
a midline calcification.
High-resolution chromosome analysis (approxi-
mately the 850-band stage) of lymphocytes from MDS
patients was performed prior to construction of somatic
cell hybrids or analysis of DNA.
Table 1 summarizes the clinical diagnosis and
cytogenetic results in our MDS and ILS patients and
in three other cell lines used for mapping purposes. Clin-
ical descriptions and high-resolution cytogenetic results
for cases MDS-1, MDS-5, MDS-6, and MDS-A have
been reported elsewhere (Dobyns et al. 1983, 1984;
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Table I
Summary of Clinical Diagnosis and Cytogenetic Results
Clinical
Case Diagnosis Karyotype
MDS-9 ........ MDS Normal
MDS-6 ........ MDS Normal
MDS-1 ........ MDS ring(17)(p13.3q25.3)
MDS-11 ....... MDS del(17)(p13.108:)
MDS-A ....... MDS t(15;17)(q26;p13.108)
MDS-5 ........ MDS del(17)(p13.105:)
HO .......... Fetal demise del(17)(p13.100:)
HB .......... SMSa del(17)(pll.2p1l.2)
GM1139 ...... Normal t(15;17)(qlS;pl1.2)b
ILS-3 ......... ILS Normal
ILS-7 ......... ILS ?del(17)(p13.3:)
a SMS = Smith-Magenis syndrome (HGM9), the newly pro-
posed eponym for "17pll deletion syndrome" reported by Smith
et al. (1986) and Stratton et al. (1986).
b The reported breakpoints in GM1139, originally assigned to
17pl23, were not determined from high-resolution cytogenetic anal-
ysis and were found to be in error. Analysis with molecular probes
showed that the actual breakpoint is 17pl 1.2 within the interstitial
deletion HB (vanTuinen et al. 1987b).
Stratton et al. 1984), while MDS-9, MDS-11, ILS-3,
and ILS-7 have not been published previously. Patient
MDS-9 was born to parents that were double third cous-
ins (coefficient of inbreeding = 1/64), and he has two
normal siblings. Pregnancy was complicated by dimin-
ished fetal movements and polyhydramnios. Facial
changes, although more subtle than usual, were con-
sistent with MDS (Dobyns 1987, fig. 4; Dobyns, in
press, figs. 1B, 1E). He also has typical, severe neuro-
logic abnormalities. CT scan showed severe type I lis-
sencephaly but no midline calcification. Patient MDS-
9, like MDS-6, revealed no cytogenetic deletion of 17p
after high-resolution analysis.
Parents of MDS-11 are unrelated and have an older
son who is normal. At 6 mo, growth was low normal
(weight 5th percentile, length and head circumference
10th percentile). Facial appearance and neurologic prob-
lems were typical ofMDS. CT scan showed severe type
I lissencephaly with a small midline calcification adja-
cent to the third ventricle. High-resolution cytogenetic
analysis was abnormal: 46,XYdel(17)(p13.108:).
The parents of ILS-3 are unrelated and have no other
children. ILS-3's facial appearance was normal except
for bitemporal hollowing, small jaw, and epicanthal
folds (Dobyns 1987, fig. 2; Dobyns, in press, figs. 2A,
2D). CT and MRI scans show type I lissencephaly with
symmetric macrogyria posteriorly and no calcification
(Dobyns 1987, fig. 2). ILS-3 had no visible deletion
of 17p by high-resolution analysis;
The parents of ILS-7 also were unrelated without
other children. ILS-7's facial appearance was normal
except for bitemporal hollowing and slight prominence
of the metopic region. CT scan showed rather severe
type I lissencephaly but without calcification. High-
resolution analysis of ILS-7 was not definitive in that
a subtle discrepancy between the two 17 homologues
was suspected in the region 17p13.3 in some cells. This
discrepancy was near the range expected for normal
contraction variation; thus, the possibility of a small
cytogenetic deletion in this patient could not be ruled
out.
Somatic Cell Hybrids
Previously described (Su et al. 1984) polyethylene-
glycol methods of somatic cell fusion were used to gener-
ate hybrids between mouse thymidine kinase-deficient
(Tk-) cells and human fibroblast or lymphoblast cell
lines bearing a variety of deletions or translocations
of 17. Included are three MDS cell lines with deletions
of 17p useful for direct mapping of probes to the MDS
critical region. An additional set of hybrids (BR-4, BR-7,
and BR-8) was constructed from an MDS male show-
ing no visible deletion, a result affording a direct test
for submicroscopic deletions in this patient. Hybrids
were isolated in hypoxanthine-aminopterin-thymidine
(HAT) to retain chromosome 17 or derivatives thereof.
One hybrid (MH-22) retained a normal chromosome
17 as the only human material (vanTuinen et al. 1987b)
and was useful in rapid confirmation of assignment to
chromosome 17. Cytogenetic analysis of somatic cell
hybrids was performed as described elsewhere (vanTui-
nen et al. 1987b). Twenty cells from each hybrid were
analyzed from G-banded preparations. Selected cells
were destained and sequentially G-11 stained to iden-
tify all human material (Alhadeff et al. 1977).
Probes
Cloned genes and anonymous clones already mapped
to 17p were investigated for localization within MDS
deletions. Three cloned genes previously mapped to dis-
tal 17p were localized: RNA polymerase II (RNA PO2A)
(Cannizzaro et al. 1986), myosin heavy-chain 2 (MYH2)
(Rappold and Vosberg 1983), and tumor antigen TP53
(TP53) (McBride et al. 1986). HF12-2 (D17S1),
YNZ22.1 (D17S5), YNH37.3 (D17S28), and MCT35.1
(D17S31) are polymorphic anonymous probes previ-
ously mapped to 17 by linkage analysis (Nakamura et
al., in press). 144-D6 (D17S34) was mapped to 17 by
somatic cell hybrids and in situ hybridization by Kon-
doleon et al. (1987). S12-30 is an alphoid satellite clone
that detects the locus D17Z1 (Willard et al., 1986); its
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isolation has been described elsewhere (vanTuinen et
al. 1987b).
Plasmid DNA was isolated by the alkaline lysis
method (Birnboim and Doly 1979). Labeling with
[32P]dCTP for hybridization to Southern blots was by
the random primer method (Feinberg and Vogelstein
1984), yielding specific activities of 0.2-1.0 x 109
cpm/Lg.
DNA Analysis
DNA from cell pellets of lymphoblast lines and so-
matic cell hybrids was extracted by routine methods
(Maniatis et al. 1982). DNA from whole blood was
extracted by the method of Grunebaum et al. (1984).
Genomic DNAs were digested with 4 U / ig of restric-
tion endonucleases, as recommended by the manufac-
turer (Boehringer-Mannheim). Agarose-gel electropho-
resis, capillary DNA transfer, hybridization, and
washing were done as described elsewhere (vanTuinen
et al. 1987b). In clinical cases not analyzed by somatic
cell hybrids and not fully informative for RFLPs, dos-
age analysis was performed by simultaneous hybrid-
ization ofthe experimental probe and a single-copy load-
ing control probe that maps to chromosome 6p (H.
Zoghbi, personal communication). Kodak XAR-5 film
was used for quantitation according to the criteria of
Laskey and Mills (1975, 1977). A Helena Laboratories
Auto Scanner was used for densitometry.
Results
Hybrid Mapping Panel
Somatic cell hybrids used to localize chromosome 17p
probes are listed in table 2. Two hybrids contain deriva-
tive or deletion 17's bearing the largest (MDS-5) and
the smallest (MDS-1) MDS deletions described so far;
a third (MDS-A) contains an intermediate-sized dele-
tion. The idiogram in figure 1 depicts the breakpoints
on 17p that we have isolated in somatic cell hybrids
and that are therefore useful in the regional mapping
of clones to 17p.
Mapping Cloned Genes
A summary of the results of hybridization of 17p
probes to somatic cell hybrids is provided in table 2
and illustrated in figure 1. Three cloned genes, MYH2,
TP53, and RNAPO2A, were mapped by the panel to
evaluate their relationship to the MDS deletions. Rep-
resentative mapping blots are shown in figure 2. All three
MDS deletion hybrids (lanes 3-5) show positive hy-
bridization to MYH2, as shown by presence of the char-
acteristic 2.3-kb human band in these lanes. The sig-
nal is present in HO-11 and HB-9 (lanes 6 and 7) but
negative in SA-5 (not shown), indicating an assignment
in the region 17pll.2-pl3.100. For TP53 the diagnostic
human band at 2.5 kb is positive in all three MDS dele-
tion hybrids but negative in HO-1i (fig. 2B). Thus, TP53
maps to the next most distal region, p13.100-pl3.105.
The results for RNAPO2A were identical to those for
TP53. Thus, all three loci map in mid or distal 17p,
close to but not within the largest MDS deletion (fig.
1). This is a significant physical distance from the criti-
cal region defined by the smallest visible deletion, the
ring 17. Therefore, these three genes are not being stud-
ied further with regard to a role in MDS.
Localization of Anonymous Clones
Five anonymous clones (HF12-2, MCT35.1, YNH-
37.3, YNZ22.1, and 144D6) were known to map to
Table 2
Concordance Patterns of Cloned Sequences and Regional Somatic Cell Hybrids
PROBE
HF12-2 MCT35.1 YNZ22.1 YNH37.3 144-D6
HYBRID (case) MYH2 (D17S1) TP53 RNAPO2A (D17S31) (D17S5) (D17S28) (D17S34)
BR-7,-8 (MDS-9) ......... + + + + + - - +
MH-74 (MDS-1) .......... + + + + + - - -
FW-1(MDS-A) . + + + + + - - -
JW-4 (MDS-5) ........... + + + + + - - -
HO-11 (fetal demise) ++...... + +
HB-9 (SMS) ............. + + + + + + + +
SA-5 (GM1139) .......... - ND - - - - - -
NOTE.-A plus sign ( + ) denotes presence of hybridizing signal; a minus sign (-) denotes absence of a hybridizing signal. ND = not
determined.
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144-D6
YNZ22
13.3 MD YNH37
13.2
13.1 c
CT35, TP53, RNRP02R
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Figure I Idiogramatic representation of breakpoints in 17p
used for high-resolution mapping in the MDS region. MDS patients
with deletion of 17pl3 are MDS-1 (breakpoint a), MDS-A and MDS-11
(breakpoint b), and MDS-5 (breakpoint c). The next most proximal
breakpoint (d) was found in a fetal demise (Greenberg et al., in press)
that has a deletion larger than that seen in MDS-5. Two breakpoints
(e) in p11.2 represent the interstitial deletion 17p11.2 of a patient with
Smith-Magenis syndrome (patient 1 of Stratton et al. 1986). GM1139
provided a breakpoint (f) allowing discrimination of probes distal
or proximal to the interstitial deletion (both hybridize positively to
the latter). The large and small brackets indicate the submicroscopic
deletion of target sequences from MDS-6 and MDS-9, respectively,
i.e., cases with normal chromosomes. The order of probes in the
clusters MYH2/HF12-2 and YNH37/YNZ22/144-D6 was previ-
ously determined by linkage analysis (Nakamura et al., in press).
Our physical localization of MCT35 is consistent with its linkage
relationship to these five probes, whereas linkage studies have not
been reported for TP53 and RNAP02A.
17p and were therefore tested for potential localization
within MDS deletions. All were confirmed to be on 17,
by hybridization to the mapping panel. HF12-2 was
present in all of the MDS and regional hybrids and there-
fore maps to 17pll.2-pl3.100. MCT35.1 maps distal
to the breakpoint at p13.100 but is present in all three
MDS hybrids. Hence it maps to the same location as
RNAPO2A and TP53 and is similarly excluded from
the MDS critical region (fig. 1).
YNZ22.1, YNH37.3, and 144-D6 mapped to a re-
gion distal to MCT35.1, HF12-2, and the cloned genes,
a result consistent with the linkage relationships of these
markers (Nakamura et al., in press). Regional mapping
for YNZ22.1 is shown in figure 2C. The 21-kb band
characteristic of the control human DNA in lane 1 is
present in lane 7 (which contains a hybrid DNA [HB-9]
with intact distal 17p), while it is absent in all three
MDS deletion hybrids (lanes 3-5). The results were
identical for YNH37.3 and 144-D6 (fig. 1; table 2),
demonstrating that all three clones map to a region
within the smallest visible MDS deletion, within the
terminal prometaphase band p13.3.
C
2.5-1"
MYH2
EcoRI
TP53
Hind III
pYNZ22.1
EcoRI
21 -
Figure 2 Hybridization ofcloned sequences to Southern blots
of the somatic cell hybrid mapping panel. For ease of interpretation
hybrid lanes are identified by "deleted" idiograms representing the
portions of 17 retained in hybrids. Lane 1, human DNA; lane 2,
mouse CUlD; lanes 3, 4, and 5, MDS deletion hybrids made from
MDS-1, MDS-A, and MDS-5, respectively; lane 6, HO-11; lane 7,
HB-9 (from SMS). The probes and the restriction endonucleases used
to reveal diagnostic human fragments are indicated on the right, while
the molecular weight (in kb) of human bands is indicated on the
left. In A and B, sequences that hybridize to mouse are present in
positions omitted from the figure. Absence of signal for YNZ22.1
in all three MDS deletion hybrids indicates that it maps to the MDS
critical region.
Deletion analysis of a fourth MDS case (MDS-11)
with a visible cytogenetic deletion was performed with-
out construction of somatic cell hybrids. Dosage anal-
ysis ofYNH37.3 and YNZ22.1 indicated that only sin-
gle copies of the target sequences were present in the
proband (table 3). RFLP analysis was conclusive for
144-D6, which was hemizygous in the proband and
indicated failure to inherit a paternal allele (not shown).
Anonymous Clones Detect Submicroscopic Deletions
Since these three anonymous probes lie within the
critical region defined by visible MDS deletions, we next
tested the possibility that they would reveal sub-
microscopic deletions in two cytogenetically normal
MDS patients. We took advantage of the highly poly-
morphic nature of these probes and attempted to an-
swer this question by using RFLPs at these loci. Failure
to inherit an allele from one parent would indicate a
de novo deletion in the chromosome 17 contributed
by that parent.
144-D6 was fully informative in the family ofMDS-9
and is heterozygous in the proband (table 3); therefore
it is not deleted. For YNH37.3 and YNZ22.1 the DNA
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Table 3
Deletion Analysis by RFLPs and Densitometry
PROBE
CASE KARYOTYPE DIAGNOSIS YNZ22.1 YNH37.3 144-D6
MDS-11 ... del(17)(p13.108:) MDS 1.02X 1.11X Hemizygous (paternal del)
MDS-6 ... Normal MDS 0.97X Hemizygous (paternal del) 0.87X
MDS-9 ... Normal MDS Hemizygous (paternal del) ... Heterozygous
ILS-3. Normal ILS 2.40X 2.27X Heterozygous
ILS-7. ?del(17)(p13.3:) ILS Heterozygous Heterozygous Heterozygous
NOTE. - Inheritance of alleles from both parents (heterozygous) or from one parent only (hemizygous) in informative families is so indi-
cated. Parental origin is indicated in parentheses. In probands with inconclusive RFLP results, the numbers represent copy number, stan-
dardized from densitometric scanning of the test probe relative to a standard probe.
a Patient shared a band with both parents that could not be separated from the other alleles of the parents, precluding densitometry
(see fig. 3). Paternal deletion for YNH37.3 was demonstrated by somatic cell hybrid analysis (table 2).
analysis of the affected male, his parents, and two sib-
lings is shown in figure 3. Both parents are heterozy-
gous for YNH37.3 and share an allele at 2.9 kb (fig.
3A). Since the child has one band at 2.9 kb, he could
be either hemizygous or homozygous for the probe. The
RFLP data are therefore inconclusive regarding dele-
tion ofprobe YNH37.3 from this patient. Dosage anal-
ysis could not be performed in MDS-9 with YNH37.3,
owing to the inability to discriminate the closely spaced
parental alleles.
For YNZ22.1 the mother is heterozygous for alleles
at 1.7 and 1.9 kb, and the father is homozygous for
an allele at 1.1 kb (fig. 3B; table 3). The child has a
single band, at 1.7 kb, from the mother but no paternal
bA B
-1.9
-1.73.2-
2.9
...
.1 -I .
pYNH37.3 pYNZ22.1
Figure 3 Hybridization of YNH37.3 (A) and YNZ22.1 (B)
to DNAs of a cytogenetically normal MDS patient (MDS-9), indi-
cated by a black square, and his family members. In A, the proband
has a single band at 2.9 kb for YNH37.3 shared by both parents,
a result consistent with homozygosity or hemizygosity for the locus.
In B, RFLP analysis for YNZ22.1 is fully informative. Both normal
siblings inherited a 1.7-kb allele from their mother and a 1.1-kb allele
from their father. The proband inherited the 1.7-kb allele from his
mother but failed to inherit a 1.1-kb allele from the father, suggesting
paternal deletion. All genomic DNAs were digested with BamHI.
band at 1.1 kb, indicating he failed to receive a paternal
allele. Although these data are consistent with a de novo
deletion of the paternal 17, they could also be explained
by nonpaternity. To exclude the latter possibility and
to clarify the results ofYNH37.3, two approaches were
pursued. First, paternity testing (conducted by Dr. M.
Pollack, Baylor College of Medicine) was performed
using a standard panel ofHLA and six red cell genetic
markers. The results showed a probability of paternity
of 99.8%, making paternal deletion the more likely ex-
planation for the YNZ22.1 data.
Second, to demonstrate deletion by the most direct
means, somatic cell hybrids were constructed from the
affected child and tested for the presence of the three
probes. Since the two 17's in the subject cannot be dis-
tinguished cytogenetically, we used the highly poly-
morphic alphoid probe S12-30 to discriminate the pater-
nal and maternal 17 homologues in the hybrids. In terms
of the major haplotype categories suggested by Willard
et al. (1986) and further illustrated by Willard et al.
(1987), the father of the affected boy has haplotypes
1/1 (prominent 2.7-kb band only) while the mother
has haplotypes 1/2 (2.7-kb band/2.0- and 1.5-kb
bands) (fig. 4A). The affected child has haplotypes 1/2;
therefore the paternal (haplotype 1) and the maternal
(haplotype 2) homologues can be easily distinguished.
Three hybrids were identified that retained intact
chromosome 17's, and the results of Southern hybrid-
ization of these DNAs are shown in figure 4A. Hybrid
BR-4 retained both chromosome 17's on cytogenetic
analysis, consistent with a Southern blot pattern (1/2)
that was identical to the genomic pattern of the affected
male. It was therefore uninformative in deletion analy-
sis. Hybrids BR-7 and BR-8 both had a single intact
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X.X m m 2
A
2.7
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Figure 4 Hybridization of the alpha satellite
and YNH37.3 (B) to hybrids containing chromosome
netically normal MDS patient MDS-9. In A, comp
ents' and the affected child's alpha satellite bandit
that the paternal and maternal haplotypes of the chi
17's can be distinguished (see text). Hybrid BR-4 ]
rental 17's on cytogenetic analysis, consistent with
pattern, while hybrids BR-7 and BR-8 retained the
In B, YNH37.3 is detected only in hybrid BR-4 ret
mosome 17's but is absent from both hybrids retaininE
17. Genomic DNAs in A were digested with EcoR]
digested with BamHI.
chromosome 17 and haplotype 1 (2.7-k
on Southern analysis, consistent with ret
the paternal chromosome 17. These two
show no hybridization to probe YNH3
establishing that the affected child's p
deleted for sequences detected by this pro
was stripped and rehybridized with YNZ2
tical results (table 2), confirming the RI
gesting deletion of this probe.
In the family ofMDS-6, both parents v
gous for different alleles of YNH37.3; 3
kb in the mother and 3.0 kb and 3.25 kb
Distinction between these alleles was confi
parison of their migration to that of a non
standard probe detecting a target sequei
which was hybridized simultaneously to
proband inherited the 3.3-kb allele fror
but inherited no paternal allele. For both'
144D6, RFLP analysis was not completel'
as the proband possessed a band shared
ents. Densitometric analysis (table 3) indic
probes are present in only one copy in
confirming a deletion. Thus, all three prol
in MDS-6, and, as in MDS-9, the deleti4
in origin.
No Deletion Detected in ILS Patients
In contrast to the results of deletion analysis for MDS,
analysis of two ILS patients showed that neither was
deleted for YNZ22.1, YNH37.3, or 144-D6 (table 3).
Patient ILS-7 was heterozygous for all three probes;
a-Satellite therefore no deletion of target sequences occurred. Pa-
tient ILS-3 was heterozygous for 144-D6 but not fully
informative for the other two probes. However, dosage
analysis indicated no deletion of either probe.
Discussion
pYNH37.3 We have constructed a somatic cell hybrid regional
mapping panel for the efficient mapping of cloned se-
probe S12-30 (A) quences to the MDS critical region. Using the panel,
e 17's from cytoge- we excluded three cloned genes from the critical region,larison of the par-
rg patterns show precluding their use in diagnosis and arguing against
ild's chromosome their direct involvement in this disorder. We have, how-
retained both pa- ever, identified three anonymous clones that are deleted
the hybridization in each of four cytogenetically visible deletions as-
paternal 17 only. sociated with MDS, including the smallest cytogeneticlining both chro- deletion described in this disorder. In addition, a com-gonly the paternal[; those in B were bination of three independent methods revealed a de
novo deletion for two of these (YNZ22.1 and YNH-
37.3) in two MDS patients with normal chromosomes.
This finding confirms and more narrowly defines an
cb band only) MDS critical region previously postulated on
ention of only cytogenetic grounds. It establishes the existence of sub-
hybrid clones microscopic deletions in MDS and suggests that the
o7.3 (fig. 4B), incidence of deletion in MDS is higher than that re-
maternal 17 is vealed by cytogenetic analyses alone. MDS thus rep-
)be. This filter resents a mental retardation/microdeletion syndrome
2.1 with iden- in which molecular detection is achieved in the absence
FLP data sug- of visible cytogenetic deletion.
vere heterozy- Clinical Implications of MDS Probes
.2 kb and 3.3 All eight MDS cases studied in our laboratory have
in the father. deletions detected cytogenetically and/or by molecular
irmed by com- analysis, arguing against a monogenic etiology for
ipolymorphic MDS. The deletion probes will therefore be a valuable
nce of 4.0 kb adjunct to high-resolution cytogenetic analysis in the
the filter. The diagnosis of MDS. Since small deletions are particu-
n the mother larly difficult (or impossible) to detect even with high-
YNZ22.1 and resolution chromosome analysis, use of molecular
y informative, probes for RFLP or dosage analysis may in some cases
by both par- be easier and more reliable than cytogenetic analysis.
ated that both However, RFLP or dosage analysis cannot completely
the proband, replace cytogenetic analysis, for a significant propor-
bes are deleted tion of MDS cases are due to parental translocation
on is paternal or inversion, which are not detectable by molecular
methods. Therefore, in determining the nature and ori-
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gin of an MDS deletion, cytogenetic analysis is neces-
sary to distinguish inheritance of an unbalanced familial
rearrangement from de novo rearrangement.
Prior to the recognition of MDS as a chromosome
deletion syndrome, a 25% recurrence risk was given
to parents of MDS patients, under the assumption of
autosomal recessive inheritance. With the availability
of cytogenetic analysis, de novo deletions can be as-
signed a negligible risk of recurrence. Although the risk
in translocation or inversion families remains substan-
tial, prenatal diagnosis by amniocentesis or chorionic
villus sampling can be offered (Stratton et al. 1984).
The results of molecular analysis that are presented
here further reduce the number ofMDS cases that could
be attributable to a hypothetical autosomal recessive
phenocopy with a 25% recurrence risk. In our two
cytogenetically normal MDS cases molecular detection
of a de novo submicroscopic deletion implies instead
a negligible recurrence risk, with dramatically contrast-
ing implications for genetic counseling. The possibil-
ity remains that all future cases studied with probes
will prove to have deletions, completely excluding au-
tosomal recessive inheritance as a cause of MDS.
Molecular Dissection of a Contiguous Gene Syndrome
We estimate that the four MDS visible deletions range
in size from less than 3 x 106 to 7 x 106 bp. Although
we do not have a direct estimate of the size of the sub-
microscopic deletions (MDS-6 and MDS-9) detected
by molecular methods only, YNZ22.1 and YNH37.3
exhibit a recombination fraction of .01 (average of both
sexes) (Nakamura et al., in press). If 1 cM = 1 x 106
bp in this region of the genome, then a cytogenetically
undetectable deletion encompassing both probes may
be of the order of 1 x 106 bp in extent-or less if the
17p terminus is highly recombinogenic. This is below
the threshold (2-3 x 106 bp) of microscopic detection.
The high incidence of demonstrable deletion in MDS
(eight of eight patients or sibships in our experience)
is perhaps best explained by a requirement for deletion
of more than one locus for expression of the syndrome.
The uniformity of the MDS phenotype despite differ-
ent deletion sizes suggests that few, perhaps only two,
genes separated by 1 x 106 bp or less must be deleted
for expression of the complete MDS phenotype.
If MDS and ILS may be thought of as related syn-
dromes with a shared, major manifestation of lissen-
cephaly, an analogy with other microdeletion syn-
dromes is appropriate. In our experience, MDS is a
clinically homogeneous syndrome, except that patients
with large deletions and/or associated duplications have
more abnormalities. ILS is probably heterogeneous
(Dobyns 1987). However, the phenotype of ILS patients
with relatively severe lissencephaly is almost identical
to that of MDS, except for the facial changes. Thus,
some cases of ILS could be due to dysfunction of a ma-
jor "lissencephaly" gene located within the MDS criti-
cal region. If so, the different mechanisms involved in
production of the MDS versus the ILS phenotypes may
be separable at a molecular level. However, in testing
the possibility that ILS patients might manifest sub-
microscopic deletion of 17pl3, we found no deletion,
in either of our two patients, with any of the three probes
that detected MDS deletions.
Two alternative explanations may be offered for this
negative finding. ILS will not be expected to reveal de-
letion of 17p if it has an etiology distinct from that of
MDS. However, since there may be a large portion of
the MDS critical region not directly covered by only
two plasmid probes, ILS deletions very much smaller
(i.e., << 1 x 106 bp) than those seen in MDS might
escape detection on conventional Southern blots using
these probes. These results are therefore not inconsis-
tent with the existence of small undetectable deletions
affecting loci associated with lissencephaly yet not large
enough to include loci responsible for the facial dys-
morphology characteristic of MDS. Saturation of this
area with additional probes could rule out deletions
in this lower size range. The amount of DNA covered
could also be increased by one or two orders of magni-
tude by applying pulsed-field gel electrophoresis after
DNA cleavage by infrequently cutting restriction en-
donucleases (Anand 1986).
Note added in proof: Three additional MDS patients
without cytogenetically detectable deletions have been
analyzed, all of whom demonstrate deletions for
YNZ22.1 and YNH37.3. To date, 13 of 13 MDS pa-
tients in our sample series have molecular deletions.
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